We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.22 | -0.15% | 149.70 | 149.89 | 147.82 | 149.89 | 6,532,721 | 00:38:06 |
From Nov 2023 to May 2024
1422 ET -- Johnson & Johnson is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The healthcare products and pharmaceuticals giant expects 2024 sales to increase 5% to 6% with adjusted EPS of $10.55 to $10.75. From 2025 through 2030, Johnson & Johnson sees Enterprise compound annual sales growth of 5% to 7%, including at least 3% operational sales growth in 2025, despite the entry of a Stelara biosimilar in the U.S. MedTech operational sales are projected to rise 5% to 7% through 2027 and Innovative Medicine operational sales growth from 2025 to 2030 is seen at 5% to 7%. Dow Jones & Co. owns Factiva. (jennifer.tershak@wsj.com)
(END) Dow Jones Newswires
December 05, 2023 14:37 ET (19:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
